UPDATE: Bank of America Downgrades ResMed to Neutral on Valuation
Bank of America downgraded ResMed (NYSE: RMD) from Buy to Neutral.
Bank of America said, "Key result metrics of Revenue / NPAT / EPS were +4% / +2% / +2% better than BofAML and +3% / +4% / +3% stronger than Consensus. The increased Gross Margin of 61.8% (+40bps sequentially) met our forecast and beat Consensus (61.2%) reaffirming our views around product mix shift and RMD's ongoing success in the APAP category. RMD's momentum in this area is being driven by factors such as the ongoing move to Home Sleep Testing (HST), now 25% of the market, and reimbursement justification changes that are becoming based on patient compliance. Despite this, and our slight earnings upgrade, we cannot find sufficient new valuation upside to maintain our Buy call and downgrade to Neutral."
ResMed closed at $45.47 on Thursday.
Latest Ratings for RMD
|Sep 2016||Bank of America||Upgrades||Neutral||Buy|
|Sep 2016||JP Morgan||Downgrades||Overweight||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.